Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

•Bridging chemotherapy is used during the manufacture of cimeric antigen receptor T cells.•Grade ≥3 infection is greater in patients following ≥2 cycles of bridging therapy.•Overall survival is lower following ≥2 cycles of bridging therapy.•Pretreatment disease burden is not reduced with ≥2 cycles of bridging therapy.